Search clinical trials for: BI 730357 (Reference)

Total 2135 results

Boehringer Ingelheim

Completed

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body

Healthy | Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body

Healthy | Chronic Kidney Disease

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Netherlands
Boehringer Ingelheim

Completed

Weekly BI 836880 in Patients With Advanced Solid Tumors

Neoplasms

Spain, France
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours

Neoplasms

Hungary
Boehringer Ingelheim

Completed

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse

Leukemia, Myeloid, Acute

United States
Boehringer Ingelheim

Completed

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Wet Macular Degeneration

Austria, Germany, Hungary
Boehringer Ingelheim

Completed

Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

BI 811283 in Various Solid Tumours

Neoplasms

Germany
GlaxoSmithKline

Completed

Dental Plaque Removal Ability of Prototype Power Toothbrush Versus a Manual Toothbrush in Healthy Participants

Dental Plaque

Canada
Clinical Nutrition Research Centre, Singapore

Completed

The Effect of Degree of Rice-polishing on Glycaemic Response

Obesity | Diabetes Mellitus

Singapore
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine
University Hospital, Bordeaux

Completed

Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses (ABPA-MR)

Allergic Bronchopulmonary Aspergilloses

France
Daewon Pharmaceutical Co., Ltd.

Completed

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809

Osteoarthritis | Rheumatoid Arthritis | Back Pain | Acute Upper Respiratory Tract Infection

Korea, Republic of
Petra Larmo
Cliniscan Ltd

Terminated

Effects of a Berry Oil Cream on Atopic Eczema and Skin

Atopic Dermatitis Eczema

Finland
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects

Healthy Volunteers

Germany
Nerviano Medical Sciences

Terminated

PHA-739358 for the Treatment of Multiple Myeloma

Multiple Myeloma

United States, France
OSE Immunotherapeutics
Boehringer Ingelheim

Active, not recruiting

A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Solid Tumor, Adult

France, Belgium
Boehringer Ingelheim

Completed

A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer

Neoplasms

Japan
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour

Neoplasms

Belgium
Boehringer Ingelheim

Terminated

Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers

Healthy

Germany
Peking University

Unknown

Screening and Treatment of SAHS in Patients With Acute Ischemic Stroke (SAHS)

Ischemic Stroke | Sleep Apnea Syndrome

China
The Affiliated Hospital of Qingdao University

Not yet recruiting

Bioequivalence Study of Bilastine Tablets in Healthy Chinese Subjects

Healthy
Boryung Pharmaceutical Co., Ltd

Completed

A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016C" With "BR1016D" in Healthy Volunteers

Chronic Heart Failure

Korea, Republic of
University of Padova
Catholic University of the Sacred Heart; University of Florence; Università degli...

Completed

Effectiveness of an Interactive Cognitive Support Tablet App to Improve the Management of Pediatric Cardiac Arrest (PediAppRREST)

Cardiac Arrest

Italy
Daewon Pharmaceutical Co., Ltd.

Completed

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809-T2

Osteoarthritis | Rheumatoid Arthritis | Back Pain | Acute Upper Respiratory Tract Infection

Korea, Republic of
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy Volunteers

Healthy

Mexico
Boehringer Ingelheim

Withdrawn

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids

Asthma
Oystershell NV

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of a New Suffocating Head Lice Product.

Head Lice | Pediculosis Capitis

United States
University of Pittsburgh

Completed

Patient Preference Survey for Radiation Oncologists

Breast Cancer | Lung Cancer | Prostate Cancer

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 730357 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee

Osteoarthritis

Germany
Boehringer Ingelheim

Completed

Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers

Healthy

Germany
Duke University

Completed

The Treatment Preferences of Women Diagnosed With Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Solid Tumor, KRAS Mutation

United States, Taiwan, Japan
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

Glioma

Spain, United States, Germany, Netherlands, Austria, Switzerland
Boehringer Ingelheim

Completed

A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

Neoplasms

United States, Canada, United Kingdom
Boehringer Ingelheim

Completed

A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer

Gastrointestinal Neoplasms | Pancreatic Neoplasms | Cholangiocarcinoma

Spain, Belgium, China, United States, Germany, Korea, Republic of, France, Japan
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1810631 is Taken up in the Body When Taken With or Without Food

Healthy

Germany
University of Pennsylvania

Withdrawn

Usability Testing of a Bilateral Activities of Daily Exercise Robot for Stroke Therapy (BiADLER)

Stroke | Cerebral Palsy

United States
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

Solid Tumors, KRAS Mutation

Japan
Boehringer Ingelheim

Completed

BI 2536 Second Line Monotherapy in SCLC

Carcinoma, Small Cell

United States, Canada
Boehringer Ingelheim

Completed

A Study to Test How Food Influences the Amount of BI 1291583 in the Blood of Healthy Men

Healthy

Germany
Boehringer Ingelheim

Completed

Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers

Neoplasms

Taiwan
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types

Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer

Neoplasms

Canada, Netherlands
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment

Hepatitis C

Germany

3

Subscribe